Loading...

SNDX SYNDAX PHARMACEUTICALS INC Product Launches 8-K Filing

SYND

SNDX

SYNDAX PHARMACEUTICALS INC

(SNDX)

2024 8-K

Financial Results Announcement

Financial Update

Bylaw Amendments

Financial Results

FDA Approval Announcement

Financial Statements

Financial Statements

Financial Results

Positive Trial Results

Financial Results

Royalty Sale Agreement

Financial Results Announcement

Appointment and Resignation

Financial Results Announcement

Appointment of Chief Commer...

Financial Results Announcement

Public Offering

Agreement for Stock Issuance

Updates on Clinical Programs

Financial Results Announcement

Financial Results Announcement

Product Updates

Termination of Sales Agreem...

Amendment to Certificate of...

Financial Results Announcement

Appointment and Resignation

Financial Results Announcement

Approval of 2023 Inducement...

External Links:

Syndax Pharmaceuticals announced FDA approval for Revuforj, the first menin inhibitor for treating relapsed or refractory acute leukemia with KMT2A translocation in patients aged one year and older, and will hold a conference call regarding this announcement.

AI Assistant

SYNDAX PHARMACEUTICALS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.